⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722291 | 0.76 | — | — | |
| SCHEMBL2871663 | 0.57 | — | — | |
| SCHEMBL11591116 | 0.57 | THRB (0.47) | — | |
| SCHEMBL7657752 | 0.57 | — | — | |
| SCHEMBL30802277 | 0.57 | — | — | |
| SCHEMBL11664208 | 0.57 | CYP3A4 (0.60) | — | |
| SCHEMBL12124166 | 0.57 | PTK2 (0.47) | — | |
| SCHEMBL14164523 | 0.57 | — | — | |
| SCHEMBL107641 | 0.57 | PTK2 (1.00) | — | |
| SCHEMBL14825159 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739689-A1 | NOVEL BISPIDINE-BASED METAL CHELATING LIGANDS DISPLAYING GOOD RELAXIVITY | Université de Strasbourg (FR) | 2026-05-13 | — | — | EP | claimed |
| WO-2025008432-A1 | NOVEL BISPIDINE-BASED METAL CHELATING LIGANDS DISPLAYING GOOD RELAXIVITY | UNIVERSITE DE STRASBOURG (FR) | 2025-01-09 | — | — | WO | claimed |
| EP-4488277-A1 | NOVEL BISPIDINE-BASED METAL CHELATING LIGANDS DISPLAYING GOOD RELAXIVITY | Université de Strasbourg (FR) | 2025-01-08 | — | — | EP | claimed |
| WO-2023198833-A1 | COMPOUND FOR THE INHIBITION OF THE NLRP3 INFLAMMASOME | APAXEN SA (BE) | 2023-10-19 | — | — | WO | claimed |
| EP-3142665-B1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | APAXEN (BE) | 2021-01-20 | — | — | EP | claimed |
| US-10160732-B2 | MIF inhibitors | MIFCARE (FR) | 2018-12-25 | — | — | US | claimed |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-09-11 | — | — | US | claimed |
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | claimed |
| EP-2944310-B1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-03-21 | — | — | EP | claimed |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | claimed |
| WO-2006026532-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | claimed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |